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Abstract
Background: The process of diagnosis and management of solitary pulmonary nodules (SPNs)
between 1 and 3 cm is not standardized. This multicentre study investigated how diagnosis of newly
discovered SPNs is managed in routine practice.
Methods:  We examined 11,515 radiology reports of patients undergoing chest computed
tomography (CT) at all 76 radiology centres in 18 French administrative districts covering
8,220,000 people. Information on diagnostic procedures and treatment administered from
discovery to definitive diagnosis of SPN was collected prospectively.
Results: We identified 152 cases of newly diagnosed SPNs. Follow-up was complete for 112
patients. The median number of diagnostic tests was 4 and the mean time to diagnosis was 41.4
days. Marked variability was observed in the sequence of diagnostic tests, and 8 diagnostic pathways
were identified. Patients' characteristics and radiological features of SPNs influenced the number of
tests performed. Referral by specialist, history of smoking and spiculated SPN predicted the
performance of at least one invasive procedure (P < 0.01). Definitive diagnosis was a malignant
disease in 30 patients (26%).
Conclusion: The diagnosis of SPN is a complex process that physicians approach in markedly
different ways. Implementing practice guidelines for managing the diagnosis of SPN requires
clarification.
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Background
Solitary pulmonary nodule (SPN) is a common abnor-
mality seen on radiology often detected incidentally by
chest radiography or computed tomography (CT) [1,2].
Every year, American physicians investigate an estimated
150,000 patients with pulmonary nodules [3]. Because
SPN is the initial radiographic finding in 10% to 20% of
patients with lung cancer [4], the aim of evaluation and
management is to promptly identify and bring to surgery
all patients with operable malignant nodules, while
avoiding unnecessary thoracotomy in those with benign
nodules [5]. Concern about malignancy may lead physi-
cians to adopt a surgical approach, but many radiograph-
ically detected lesions initially suspected to be cancerous
are later proven not. The proportion of cases that turn out
to be benign varied widely in published series [6]. Malig-
nant disease is estimated to occur in 20% of patients with
SPNs in the population and in 40% of those in surgical
series [3,7,8].
The process of diagnosis may include CT scanning, whole-
body positron emission tomography (PET), flexible bron-
choscopy, transthoracic needle aspiration biopsy
(TTNAB), transbronchic needle biopsy (Wang needle
biopsy), video-assisted thoracoscopy, video-assisted tho-
racoscopic surgery, and thoracotomy. TTNAB is a more
invasive way of obtaining a tissue diagnosis than bron-
choscopy and Wang needle biopsy. It is much less invasive
than surgery but also less reliable in ruling out malig-
nancy. TTNAB and bronchoscopy are diagnostic; surgical
resection has both diagnostic and therapeutic implica-
tions [9-11]. The choice of tests depends on many factors,
including clinical features, results of relevant investiga-
tions, patient characteristics, and local care policy [7,12].
Guidelines published by the American College of Chest
Physicians (ACCP) in 2003 address SPN evaluation [13],
but National Comprehensive Cancer Network (NCCN)
recommendations (v.2004) do not consider SPN as such.
Some centres opt for early explorative surgery, whereas
others carry out various imaging and invasive tests first.
The literature reflects this lack of consensus [14,15].
Concerns regarding practice variations, quality of cancer
care, and suboptimal patient outcomes seem to be well
founded [16]. A high degree of variability might exist in
the diagnostic process and management of SPNs [17].
Recent efforts have been made toward the implementa-
tion of evidence-based guidelines [18], but information
about how physicians assess patients with SPNs in every-
day practice is limited. We hypothesized that such varia-
bility in routine practice could be characterised by
structured pathways and is affected by radiological fea-
tures as well as other factors. The aim of the present study
was to establish the diagnostic pathways that follow the
discovery of SPN on chest CT to definitive diagnosis
(malignant or benign) and to determine factors in deci-
sion making about SPN management.
Methods
The present study was undertaken in an area of northeast-
ern France covering 5 regions comprising a target of 18
health administrative districts with a population of about
8,220,000 people. The study was carried out under the
auspices of the French Ministry of Health, and the study
protocol was approved by the regional ethics committee
and the national committee for confidential protection
CNIL (Commission Nationale de l'Informatique et des
Libertés). As an observational study, informed consent
was not required.
Sampling subjects with SPN
Unfortunately, the definition of an SPN is controversial in
the literature [13,19-21]. For the present study, we consid-
ered the radiologic definition described by a committee of
the Fleischner Society on CT nomenclature: "coin lesion"
or SPN defined as a "single round opacity, at least moder-
ately well marginated and no greater than 3 cm in maxi-
mum diameter". An SPN less than 1 cm and ground glass
nodules were not included in this SPN definition because
recognizing this nodules depends greatly on available
expertise and equipments [22].
A pilot study examining 268 consecutive sets of radiology
reports of chest CT at 3 radiology centres revealed that
data from these rapports supplemented with relevant
information from the medical chart of the hospital or gen-
eral practitioner [GP] were helpful in the study of SPN
diagnosis. This pilot study also indicated that examining
the results of chest CT performed for one week at each
radiology centre would yield data about a sufficient of
number of patients with SPNs in the whole area.
All the 76 radiology centres in the 18 health districts, com-
munity and teaching, public and private, used standard-
dose chest CT. They all agreed to participate in this study
over a randomly selected period of 6 consecutive weeks
from May 2002 to March 2003. In the context of usual
practice of each centre, all chests CT results were read by
the radiologists of the centre. Radiologists used theirs
locale standard criteria in reading chest CT and were
informed by the patient's referral physician about the
patient's clinical status and the results of any tests per-
formed formerly. During the 6-week period, results of
11,515 chest CTs were read by radiologists. The radiology
reports were sent to each patient's referring physician.
Five qualified clinical research assistants in charge of data
collection were trained by a panel of the study investiga-
tors to ensure homogeneous results. The research assist-BMC Cancer 2008, 8:93 http://www.biomedcentral.com/1471-2407/8/93
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ants also included each newly diagnosed SPN recorded in
the radiology reports. Cases were excluded if CT results
showed evidence of metastasis or primary malignancy
inside or outside the chest. All the included cases were ver-
ified by the panel of investigators. The GP and primary
managing hospital physician were updated every 3
months on the process of diagnosis. Clinical research
assistants collected data concerning age, sex, referring
physician (generalist, specialist), appearance of SPN as
recorded in the radiology reports (calcification within the
nodule, appearance of spiculated nodule, mediastinal
involvement or enlarged lymph nodes on CT), history of
smoking (current or past smoker, never smoked), and
dates and results of all investigations performed by the GP
or any specialist physician (excluding laboratory and lung
function tests). Diagnosis management was considered to
be specialised if performed by a radiologist, chest physi-
cian, oncologist or thoracic surgeon.
For this study, we considered that the definitive diagnosis
of SPN was established if there was histological evidence
(malignant or benign) for the diagnosis. If the physicians
involved in the patient care decided to discontinue the
process of diagnosing without histological evidence,
patients were followed up for 2 years after discontinua-
tion of the diagnosis process. The 2-year prospective fol-
lowup period was chosen because stability or no evidence
of malignant disease for at least 2 years is a reliable indi-
cator of a benign process [5,23], despite some investiga-
tors suggesting that even longer periods are necessary for
confirmation [24].
Statistical analysis
Procedures performed to establish the definitive diagnosis
of SPN were analysed. The diagnostic pathway was
defined as a set of tests used until definitive diagnosis. The
duration of the process was calculated as the interval
between the date of chest CT and that of any procedure
after which physicians discontinued the diagnosis process
of SPN. Quantitative variables are presented as median
and ranges, categorical variables as proportions. Compar-
ison of variables involved the Student's t-test or Mann-
Whitney test for quantitative variables and chi-square or
Fisher's exact tests for categorical variables.
A multivariate Poisson regression model suited to the dis-
tribution of number of tests was used to analyse the effect
of the patients' characteristics and the radiological fea-
tures of SPN on the number of tests performed before
definitive diagnosis. A multivariate logistic regression
model was used to examine the effect of the patients' char-
acteristics and the radiological features of SPN on the
probability of performance of at least one invasive test
(surgical or non-surgical), adjusting for confounding var-
iables. A multivariate Cox regression model was used to
analyse the effect of the patients' characteristics and the
radiological features of SPN on the time to definitive diag-
nosis. Two-tailed tests were applied with a significance
threshold of 0.05. The Statistical Analysis System (version
8.2; SAS Institute; Cary, NC) was used for all analyses.
Results
Subject characteristics
Analysis of 11,515 radiology reports of chest CT over the
6 weeks identified 152 cases of newly diagnosed SPN.
Patients were elderly (median 67.7 years; range 31.6–
92.4, and predominantly male (72.4%); 122 (80.3%)
were directly referred to radiology centres for chest CT by
a specialist. Among 152 newly diagnosed SPN, 40 patients
(24%) were lost to follow-up, including 6 patients who
refused other investigations and 6 who died without evi-
dence of definitive diagnosis. Baseline characteristics of
the study population and patients with no follow-up data
are in table 1. Patients without followup data were less
likely to have a current or past history of smoking.
Diagnostic procedures
For 57 patients, the benign diagnosis was based on imag-
ing tests alone without histological evidence. For 39 of
these, SPN was revealed on chest CT without further diag-
nostic procedures.
The median number of investigations was 4, and incon-
clusive test results were common. Factors with a potential
influence on the number of tests performed are presented
in table 2. In multivariate regression, the number of tests
was significantly higher in patients older than 65 years (p
= 0.02), referred by a specialist (p < 0.01), with current or
past history of smoking (p < 0.01) and with spiculated
nodules (p = 0.01).
Apart from CT of the chest, imaging tests carried out were
(in decreasing order of frequency) 31 CT of complete
abdomen (27.6%); 19 CT or magnetic resonance imaging
of the brain (16.9%); 18 ultrasonography of abdomen
(16%); 10 bone scan (8.9%); 5 CT of cervix (4.4%) and 2
whole-body positron emission tomography (1.7%). In 25
cases, an imaging test was repeated at least once before a
definitive diagnosis was reached.
Fifty-five patients underwent invasive diagnostic tech-
niques to evaluate SPN 48 flexible bronchoscopy
(42.8%), 9 transthoracic needle aspiration biopsy (8%), 3
transbronchic (Wang) needle biopsy (2.7%) and 10
exploratory thoracotomy (8.9%). In 15 cases, an invasive
test was repeated at least once before a definitive diagnosis
was reached.BMC Cancer 2008, 8:93 http://www.biomedcentral.com/1471-2407/8/93
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Diagnostic pathways
A high level of variability was observed in the sequence of
tests performed. Eight diagnostic pathways were identi-
fied. They fell into 3 categories: pathways based on imag-
ing alone, with no invasive investigations (noninvasive);
those based on at least 1 surgical procedure (invasive sur-
gical); and those based on at least 1 invasive nonsurgical
procedure (invasive nonsurgical) (Fig. 1). For 57 patients,
the process of diagnosis was non-invasive and for 55 inva-
sive (surgical and nonsurgical). In 33 cases, the definitive
diagnosis was made from bronchoscopy after chest CT.
Chest CT followed by TTNAB was sufficient to establish
the definitive diagnosis in 4 patients.
Table 1: Characteristics of patients with newly diagnosed SPN.
Variable Patients with followup Patients without followup p
Median (range) N % Median (range) n %
Age (yr) 67.7 (31.6–92.4) 112 70.4 (34.3–89.6) 40 0.44
Sex
Male 82 73.2 28 70.0 0.70
Female 30 26.8 12 30.0
Referral pattern
GP 18 16.1 12 30.0 0.06
Specialist 94 83.9 28 70.0
Smoking habits
Never smoked 33 29.5 23 57.5 <0.01
Current or past smoker 79 70.5 17 42.5
Nodule characteristics
Calcification within the nodule 12 10.7 1 2.5 0.11
Spiculated nodule 32 28.6 16 40.0 0.18
Mediastinal involvement 31 27.7 13 32.5 0.56
GP = General Practitioner*
Table 2: Number of tests performed prior to diagnosis according to patients and nodule characteristics (median and range).
Factor n No. tests prior to diagnosis p# p##
Patient characteristics
Age(yr)
35–65 52 3 (1–14) 0.43 0.02
> 65 60 4 (1–21)
Sex
Male 82 4 (1–21) 0.22 0.86
Female 30 3 (1–12)
Referral pattern
GP 18 2 (1–6) <0.01 <0.01
Specialist 94 4 (1–21)
History of smoking
Never smoked 33 2 (1–12) <0.01 <0.01
Current or past smoker 79 5 (1–21)
Nodule characteristics
Calcification within the nodule
Yes 12 2 (1–14) 0.04 0.76
No 100 4 (1–21)
Spiculated nodule
Yes 32 5 (1–14) 0.02 0.01
No 80 3 (1–21)
Mediastinal involvement
Yes 31 4 (1–21) 0.4 0.19
No 81 4 (1–12)
GP = General Practitioner.
p# In Mann-Whitney test.
p## In multivariate Poisson regression model.BMC Cancer 2008, 8:93 http://www.biomedcentral.com/1471-2407/8/93
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Determinants of diagnostic pathways
Table 3 shows the univariate and multivariate odds ratios
(ORs) of variables related to the patient characteristics
and the radiological features of SPN predicting the use of
at least one invasive test (surgical or nonsurgical). In the
univariate analysis, male sex, current or past history of
smoking, referral from a specialist physician, spiculated
nodule, and mediastinal involvement all increased the
likelihood of at least one invasive test conducted. Multi-
variate analysis showed that patients referred by a special-
ist physician (OR = 6.6) with current or past history of
smoking (OR = 32.9) and a spiculated nodule (OR = 5.7)
were significantly more likely to undergo at least one inva-
sive test (p < 0.01). A total of 30 patients (26.8%) were
given a diagnosis of cancer.
Duration of process of diagnosis
Time to definitive diagnosis was 41.4 days, on average,
and more than 30 days in 40% of cases. Among patients
exhibiting calcification within the lesion, the median time
to diagnosis was 26.5 days. Mediastinal involvement was
reported in 31 patients, among whom the median interval
between the chest CT and definitive diagnosis was 25 days
(Table 4). Cox multivariate regression analysis showed no
effect of the radiological appearance of the nodule or
patients' characteristics on time to definitive diagnosis.
Patient outcome
Among 112 patients with complete follow-up data, the
definitive diagnosis was a malignant disease in 30 patients
(26, 78%). Among 31 patients with mediastinal involve-
ment at the first observation of SPN, 16 (51, 61%) cancer
was diagnosed at the end of process of diagnosis. The
mediastinal involvement was more likely to be associated
with cancer (p = 0.005).
Table 5 shows the histological classification in the 30
patients with a definitive diagnosis of cancer as follows:
squamous cell carcinoma (13; 43.3%), adenocarcinoma
(10; 33.3%), Bronchioloalveolar carcinoma (2; 6.7%),
large cell (2; 6.7%) and Small cell lung carcinoma (1;
3.3%), SPN was the first manifestation of primary colon
cancer in one patient and of lymphoma in another. Infor-
mation regarding stage was available in 26 patients
(86.6%). The details of the stage of lung cancer at presen-
tation are shown in table 6. Lobectomy with intent to cure
was performed in 15 patients; lobectomy was also the
diagnostic test in 8 of these patients. Eight patients
Diagnostic pathways prior to definitive diagnosis of SPN Figure 1
Diagnostic pathways prior to definitive diagnosis of SPN. Numbers in parentheses are numbers of patients. (SPN = sol-
itary pulmonary nodule; CT: computed tomography; TTNAB: trans-thoracic needle aspiration biopsy; Wang: Wang needle 
biopsy; SUR: surgery; CRT: chemoradiotherapy).
Chest CT (112)
Diagnosis Treatment Diagnostic Pathways
Non-Invasive
(57)
Invasive
(55)
No other imaging test (39)
Broncoscopy (33)
Broncoscopy +TTANB (5)
TTANB (4)
Other imaging test  (18)
No Cancer (19)
Cancer (14)
No Cancer (19)
Cancer (14)
No Cancer (0)
Cancer (5)
No Cancer (0)
Cancer (5)
No Cancer (3)
Cancer (1)
No Cancer (3)
Cancer (1)
Surgery (3)
No Cancer (2)
Cancer (1)
Surgery (3)
No Cancer (2)
Cancer (1)
No Cancer (18)
No Cancer (39)
CRT (4)
SUR (4)
SUR+ CRT(6)
CRT (4)
SUR (4)
CRT (4)
SUR+ CRT (1)
CRT (4)
SUR+ CRT (1)
SUR (1)
CRT (1)
Broncoscopy+ Wang (3) 
No Cancer (1)
Cancer (2)
No Cancer (1)
Cancer (2) CRT (2)
Broncoscopy +surgery (7) 
No Cancer (0)
Cancer (7)
No Cancer (0)
Cancer (7) SUR+ CRT (2)
CRT (1)
SUR (4)
SUR+ CRT (2)
CRT (1)
SUR (4)
Broncoscopy +surgery (7) 
No Cancer (0)
Cancer (7)
No Cancer (0)
Cancer (7) SUR+ CRT (2)
CRT (1)
SUR (4)
SUR+ CRT (2)
CRT (1)
SUR (4)
Invasive  
Surgical
(10)
Invasive 
Non Surgical
(45)BMC Cancer 2008, 8:93 http://www.biomedcentral.com/1471-2407/8/93
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received chemotherapy or radiotherapy in addition to sur-
gery.
Discussion
The present paper describes the diagnostic process in a
representative sample of patients with newly diagnosed
SPN identified from 11,515 radiology reports of chest CT
at all radiology centres in northeastern France. Reflecting
physicians' usual practices, the process of diagnosing new
SPN varied widely over 8 diagnostic pathways and was
often protracted, with many patients not undergoing his-
tological examination of the SPN. The radiological fea-
tures of SPN influenced the number of tests performed
prior to definitive diagnosis and the likelihood of per-
forming at least one invasive test. Although physicians
attempted to minimise the delay until definitive diagnosis
in many cases, a considerable subset of patients under-
went a prolonged period of diagnosis and inconclusive
tests were common.
The evaluation of a solitary pulmonary nodule is com-
plex. Management decisions are based on clinical history,
size and appearance of the nodule, and feasibility of
obtaining a tissue diagnosis, so some variability in man-
agement may be justified as many considerations must be
taken into account in diagnosing SPN. Abnormality of
any form seen on chest CT is a worry for the patient during
the entire process. So differences in patient's preference
for imaging or an invasive test might affect physician deci-
sion making. In a large population, as in this study of 8
million people potentially referable for chest CT, local
policy of the centres and education of physicians involved
in the management of SPN can account for physicians'
differing choices for tests and the high number of tests
performed. Since a criterion standard pathway does not
exist and guidelines do not recommend a "good practice"
sequence of diagnostic tests, investigations ordered for
SPN diagnosis might reflect the physician's own aware-
ness of the options and their cost. Reasons for variations
observed in practices can be grouped into three categories:
those related to professional uncertainty, to external con-
straints, and to diffusion of new knowledge and practices.
Combinations of clinical factors such as the characteristics
of nodules, and structural ones such as the availability of
resources, lead to different local standards of medical care.
The present findings are in accordance with previous stud-
ies describing high variation in physician practice patterns
in other settings [25].
To date, no published data exists on the diagnostic path-
ways for SPN. Our study differs in many ways from the
few others that have examined the diagnostic manage-
Table 3: Factors influencing whether patients with SPN undergo at least one invasive test (Odds ratio [OR] and 95% confidence 
interval [CI]).
Factor n Unadjusted OR of receiving invasive test (CI)* Adjusted OR of receiving invasive test (CI)+ P$
Patient characteristics
Age
35–65 52 0.8 (0.3–1.7) 1.5 (0.5–4.3) 0.38
> 65 60 1 1
Sex
Male 82 2.9 (1.2–7.2) 0.5 (0.1–3.8) 0.57
Female 30 1 1
Referral pattern
Specialist 94 4.1 (1.2–13.5) 6.6 (1.4–30.3) 0.01
GP 18 1 1
History of smoking
Current or past smoker 79 19.2 (5.3–68.8) 32.9 (4.3–247.7) <0.01
Never smoked 33 1 1
Nodule characteristics
Calcification within the nodule
Yes 12 0.1 (0.1–0.8) 0.5 (0.1–4.2) 0.54
No 100 1 1
Spiculated nodule
Yes 32 4.7 (1.8–11.8) 5.7 (1.6–19.5) <0.01
No 80 1 1
Mediastinal involvement
Yes 31 1.9 (0.8–4.6) 1.4 (0.4–4.3) 0.49
No 81 1 1
GP = general practitioner
*In univariate logistic regression models
+In multivariate logistic regression model
$p values for the factors are the Wald statistics for the estimates in the modelBMC Cancer 2008, 8:93 http://www.biomedcentral.com/1471-2407/8/93
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ment of SPN. First, our study is based on information
from randomly selected radiology reports representative
of a large population in 18 health districts and therefore
reflects usual practice in France and is not biased by the
selection of cases. Clearly, only patients with nodules with
suggestive characteristics seen on imaging are referred to a
specialised centre to undergo surgery for characterization,
and, thus, studies based on such data have a marked selec-
tion bias. Second, our search included the results of all
chest CT. Thus, many of the SPNs were incidental findings
on chest CT. In the radiology literature, studies of SPN
have been developed in the context of lung cancer screen-
ing programs [20,21,26]. However, subjects who undergo
lung cancer screening in most countries are selected on
the basis of age, substantial smoking history, absence of
serious co-morbid disease, and willingness to participate
in all necessary follow-up imaging and intervention.
Moreover, these programs tend to have a standardized
protocol for follow-up of subjects and for early cure.
Therefore, subjects whose nodules are detectedinciden-
tally during chest CT performed for other reasons should
not necessarily be managed in the same way as subjects in
a screening program.
The literature reports important variations in the defini-
tion of the time to definitive diagnosis of subjects with
suspected lung cancer. Different intervals were used, from
Table 4: Time between first test and diagnosis according to nodule characteristics. (Median and interquartile).
Factor n Days to diagnosis p# p##
Patient characteristics
Age
35–65 52 24 (4–61.5) 0.5 0.33
> 65 60 28 (11.5–53.5)
Sex
Male 82 26 (8–63) 0.4 0.42
Female 30 25.5 (0–46)
Referral pattern
GP 18 18 (0–33) 0.10 0.07
Specialist 94 28 (8–62)
History of smoking
Never smoked 33 13 (0–35) <0.01 0.17
Current or past smoker 79 29 (11–63)
Nodule characteristics
Calcification within the nodule
Yes 12 26.5 (5–51) 0.4 0.34
No 100 25.5 (0–25.5)
Spiculated nodule
Yes 32 33 (25.5–65.5) 0.02 0.41
No 80 14.5 (3.5–56.5)
Mediastinal involvement
Yes 31 25 (11–62) 0.29 0.74
No 81 27 (6–61)
GP = General Practitioner
p# In Mann-Whitney test.
p## In multivariate Cox regression model.
Table 5: The histological classification in the 30 patients with a 
definitive diagnosis of cancer.
Histological type n %
Squamous cell carcinoma 13 43.3
Adenocarcinoma 10 33.3
Bronchioloalveolar carcinoma 2 6.7
Large cell carcinoma 2 6.7
Small cell lung carcinoma 1 3.3
Lymphoma 1 3.3
Unspecified lung cancer 1 3.3
Table 6: The stage of disease in the 30 patients with a definitive 
diagnosis of cancer.
Stage of cancer n %
IA 6 20
IB 8 26.7
IIA 1 3.3
IIB 3 10
IIIA 2 6.7
IIIB 3 10
IV 3 10
Non reported in medical report 4 13.3BMC Cancer 2008, 8:93 http://www.biomedcentral.com/1471-2407/8/93
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the first symptoms until the treatment [27,28]. These end-
points reflect the different concerns of investigators. These
clinical endpoints are all relevant but not comparable. In
regard to the diagnosis of lung cancer, our data suggest
that the interval between the initial CT and definitive
diagnosis is likely long. The need to shorten the interval to
diagnosis is likely supported by several studies [29-32].
Extended intervals between symptoms, initial chest CT,
diagnosis and surgery may give the primary tumour the
time to double in size and may increase the likelihood of
local and distant spread.
Although this investigation provides new information
about managing the diagnosis of newly discovered SPN in
routine practice, several limitations should be addressed.
First, the study protocol defined nodule as round opacity,
with a maximum diameter of 3 cm and a minimum diam-
eter of 1 cm. While this provides an idealized definition of
a lung nodule demonstrated on CT scans, the natural
complexities of biologic systems make the practical appli-
cation of such a definition difficult [33]. We used the
more possible generic term to describe a solitary pulmo-
nary nodule and this study was designed to assess all types
of nodules rather than one specific type as the first ques-
tion posed by our study investigated how SPN is managed
in daily practice. Our hypothesis was that nodule charac-
teristics and mediastinal lymph node enlargement could
influence clinician strategies to evaluate patients with pul-
monary nodule so we included the information about
mediastinal involvement in our analysis. We chose to
exclude small nodules because recognizing nodules less
than 1 cm depends greatly on available expertise and
equipment [19]. However, the clinical importance of
these small nodules differs from that of larger nodules.
This issue has been highlighted in recent publications on
CT screening for lung cancer, and the positive relationship
of lesion size to likelihood of malignancy has been clearly
demonstrated. Second, it was difficult to obtain detailed
follow-up information on some patients. Complete
records of ambulatory and hospital diagnostic procedures
were not available in 40 cases. Given that it was not pos-
sible to ascertain diagnosis at the moment of the first
detection of SPN on chest CT by the radiologists these
patients were considered as lost to follow-up. Compared
with the study population, members of this group were
less likely to be current or past smokers. The lack of a cen-
tralised patient-based information system in France led to
a relatively high proportion of cases with unavailable
data. As likelihood of cancer is low in patients without
history of smoking we could imply that physician have
less attention to require another assessment (invasive or
non invasive) for these patients. Third, some prognostic
factors, for example, a history of asbestos exposure or co-
morbid condition of patients were not taken into account.
Differences in prognosis may have accounted for the phy-
sicians' differing choices for tests. Finally, for 112 patients,
several problems arose concerning the order in which tests
were conducted. The many possibilities resulted in a
number of combinations, with some diagnostic pathways
being used in only 3 or 4 patients.
With increasing clinical governance in the health system
in France, emphasis is being placed on identifying the best
practice and avoiding delays in diagnosis of lung cancer
that are potentially detrimental to the patient[5,23], Lack
of a clear protocol for diagnosis warns of potential for fail-
ure to recognize primary malignant disease. The present
study looked at the pathways of care from the point of
referral by a radiologist recognizing the presence of SPN to
definitive diagnosis. The findings can therefore be used to
inform health service planning about real practice, to
identify areas for improvement, and to update guidelines
for managing diagnosis of SPN. Future practice guidelines
for SPN diagnosis should be supported by more evidence
and should take into account the features of SPN revealed
by chest CT and the patient's clinical characteristics. Clar-
ifications would derive more attention as initiation of
effective treatment may improve survival.
PET imaging can reveal foci of lung cancer not seen using
other imaging techniques It reported a sensitivity of
96.8% and a specificity of 77.8% for any focal lung lesion;
and figures of 93.9% and 85.8%, respectively for pulmo-
nary nodules [34,35]. PET was not available in France at
the time when this study was conducted. However some
bordering patients could be referred by the generals prac-
titioners, if need, to perform PET in a nearest foreign
country. Recently, many French hospitals have decided to
adopt it. This study provides baseline information to
measure improvements in the care of patients with SPN
after the implementation of PET imagining. Its role in
daily clinical practice as a means of simplifying and
improving the final selection of patients for surgery is cur-
rently under study.
Conclusion
In conclusion, our data suggest that the interval between
the initial CT and the definitive diagnosis of SPN is likely
long in northeastern France and efforts should be made to
shorten this interval. Specific information could be pro-
vided about which patients follow each diagnostic path-
way, but given the observational design of this study,
more work is necessary to better define a "minimally inva-
sive" optimal pathway in the definitive diagnosis of SPN.
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